These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 12873538

  • 1. Cyclosporin C(2) and C(0) concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors.
    Ray JE, Keogh AM, McLachlan AJ, Akhlaghi F.
    J Heart Lung Transplant; 2003 Jul; 22(7):715-22. PubMed ID: 12873538
    [Abstract] [Full Text] [Related]

  • 2. Decision support tool to individualize cyclosporine dose in stable, long-term heart transplant recipients receiving metabolic inhibitors: overcoming limitations of cyclosporine C2 monitoring.
    Ray JE, Keogh AM, McLachlan AJ.
    J Heart Lung Transplant; 2006 Oct; 25(10):1223-9. PubMed ID: 17045935
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors.
    Akhlaghi F, Keogh AM, McLachlan AJ, Kaan A.
    J Heart Lung Transplant; 2001 Apr; 20(4):431-8. PubMed ID: 11295581
    [Abstract] [Full Text] [Related]

  • 4. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 5. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
    Schädeli F, Marti HP, Frey FJ, Uehlinger DE.
    Clin Pharmacokinet; 2002 Jun; 41(1):59-69. PubMed ID: 11825097
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic interactions between microemulsion formulated cyclosporine A and diltiazem in renal transplant recipients.
    Asberg A, Christensen H, Hartmann A, Carlson E, Molden E, Berg KJ.
    Eur J Clin Pharmacol; 1999 Jul; 55(5):383-7. PubMed ID: 10456488
    [Abstract] [Full Text] [Related]

  • 7. Diltiazem-cyclosporin pharmacokinetic interaction--dose-response relationship.
    Jones TE, Morris RG, Mathew TH.
    Br J Clin Pharmacol; 1997 Nov; 44(5):499-504. PubMed ID: 9384468
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic drug monitoring of cyclosporine Neoral in de novo Chinese cardiac transplant recipients treated with an everolimus-cyclosporine immunosuppressive regimen.
    Wang CH, Chou NK, Wu FL, Ko WJ, Tsao CI, Chi NH, Hsu RB, Wang SS.
    Transplant Proc; 2006 Sep; 38(7):2132-4. PubMed ID: 16980022
    [Abstract] [Full Text] [Related]

  • 9. Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach.
    McLachlan AJ, Tett SE.
    Ther Drug Monit; 1998 Aug; 20(4):390-5. PubMed ID: 9712463
    [Abstract] [Full Text] [Related]

  • 10. Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem.
    Aros CA, Schneider HO, Flores CA, Ardiles LG, Alruiz PA, Jerez V, Mezzano SA.
    Transplant Proc; 2005 Apr; 37(3):1580-2. PubMed ID: 15866679
    [Abstract] [Full Text] [Related]

  • 11. [Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients].
    Sperschneider H, Wagner C, Korn A, Christians U.
    Med Klin (Munich); 1997 Oct 15; 92(10):589-96. PubMed ID: 9446006
    [Abstract] [Full Text] [Related]

  • 12. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
    Mardigyan V, Giannetti N, Cecere R, Besner JG, Cantarovich M.
    J Heart Lung Transplant; 2005 Oct 15; 24(10):1614-8. PubMed ID: 16210138
    [Abstract] [Full Text] [Related]

  • 13. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
    Jaksch P, Kocher A, Neuhauser P, Sarahrudi K, Seweryn J, Wisser W, Klepetko W.
    J Heart Lung Transplant; 2005 Aug 15; 24(8):1076-80. PubMed ID: 16102443
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients.
    Jones TE, Morris RG.
    Clin Pharmacokinet; 2002 Aug 15; 41(5):381-8. PubMed ID: 12036394
    [Abstract] [Full Text] [Related]

  • 15. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month.
    Morris RG, Russ GR, Cervelli MJ, Juneja R, McDonald SP, Mathew TH.
    Ther Drug Monit; 2002 Aug 15; 24(4):479-86. PubMed ID: 12142630
    [Abstract] [Full Text] [Related]

  • 16. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.
    Bunnag S, Vareesangthip K, Ong-ajyooth L.
    J Med Assoc Thai; 2006 Aug 15; 89 Suppl 2():S228-34. PubMed ID: 17044476
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral.
    Wang CH, Ko WJ, Chou NK, Wang SS.
    Transplant Proc; 2004 Oct 15; 36(8):2386-7. PubMed ID: 15561257
    [Abstract] [Full Text] [Related]

  • 18. A limited sampling strategy for the estimation of 12-hour cyclosporine neoral area under the curve in Chinese cardiac transplant recipients.
    Wang CH, Ko WJ, Chou NK, Wang SS.
    Transplant Proc; 2004 Oct 15; 36(8):2390-2. PubMed ID: 15561259
    [Abstract] [Full Text] [Related]

  • 19. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
    Canadian Neoral Renal Transplantation Study Group.
    Transplantation; 2001 Sep 27; 72(6):1024-32. PubMed ID: 11579295
    [Abstract] [Full Text] [Related]

  • 20. Prednisone metabolism in recipients of kidney or liver transplants and in lung recipients receiving ketoconazole.
    Jeng S, Chanchairujira T, Jusko W, Steiner R.
    Transplantation; 2003 Mar 27; 75(6):792-5. PubMed ID: 12660503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.